Pant Provides Insight on Key ASCO 2020 Data in Gastrointestinal Malignancies
Shubham Pant, MD, discusses key data that emerged in the gastrointestinal oncology space from the 2020 ASCO Virtual Scientific Program.
Shubham Pant, MD, discusses key data that emerged in the gastrointestinal oncology space from the 2020 ASCO Virtual Scientific Program.
The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.
Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Erin Frances Cobain, MD, discusses optimal endocrine therapy–based treatment strategies in later-line settings for HR-positive/HER2-negative breast cancer.
Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.